Does a BMI of 27 qualify you for Mounjaro?

Why the licence draws a line at BMI 27, and what must come with it

The UK licence for tirzepatide sets two parallel entry points. Adults with a BMI of 30 or above can be considered on that basis alone. For adults with a BMI between 27 and 29.9, the licence adds a firm condition: at least one weight-related health problem that treatment might help address. This isn't a technicality, it reflects the clinical rationale that a lower BMI warrants a demonstrated health reason for intervention.

The list of conditions that satisfy this requirement is broader than many people expect. Type 2 diabetes and prediabetes both count, as do hypertension, high cholesterol or triglycerides (dyslipidaemia), obstructive sleep apnoea and osteoarthritis. Cardiovascular disease is another. If you carry a diagnosis of any of these alongside a BMI of 27, you may well meet the licensed criteria. If you carry none of them, Mounjaro at BMI 27 falls outside its licensed use, and a responsible prescriber will tell you so clearly.

The NHS tirzepatide information page sets this out plainly, and the Summary of Product Characteristics on the electronic Medicines Compendium provides the full clinical detail for those who want to read the primary source. A practical first step: pull up how BMI thresholds work across different Mounjaro eligibility scenarios to sense-check your own position before you book anything.

Ethnic-background adjustments that may lower your qualifying BMI

UK clinical guidance recognises that BMI is an imperfect tool for assessing health risk across different ethnic groups. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, current guidance typically applies a BMI threshold 2.5 kg/m² lower than the standard figures. In practice, that means the BMI 27 threshold could effectively be 24.5 for some people, so if your BMI sits just below 27, this adjustment may still bring you within scope, provided the comorbidity condition is also met.

This isn't a loophole; it reflects evidence that the same BMI can carry different metabolic risk depending on ethnicity. A prescriber familiar with UK guidance will apply this assessment as part of a full clinical review. If you're unsure whether it applies to your background, that's precisely the kind of question to raise during your consultation rather than trying to calculate it yourself.

People sometimes ask whether BMI 25 or 26 could qualify under any reading of the current licence, the answer is that it would require both the ethnic-background adjustment and a comorbidity to be present. You can read more about how the BMI 25 scenario is assessed separately.

What a prescriber weighs up beyond the BMI number

Meeting the BMI and comorbidity criteria gets you through the first gate. It doesn't end the clinical assessment there. A prescriber reviewing a request for Mounjaro at BMI 27 will also consider your overall health history: any contraindications (a personal or close family history of medullary thyroid carcinoma or MEN2, for instance, or a history of pancreatitis), current medications, and whether the potential benefits outweigh any individual risks.

Women of childbearing age will be asked about contraception. Tirzepatide is not recommended during pregnancy or while trying to conceive, and it can reduce the absorption of oral contraceptive pills during the first four weeks of treatment and for four weeks after each dose increase, so a non-oral method as backup is usually advised for that period. These details come out through a proper consultation, not a quick online quiz.

At BMI 27, the prescriber's judgement carries more weight than it might at BMI 35, precisely because the margin between licensed and unlicensed use is narrower. That's not a barrier, it's the system working as it should. If you're considering whether this applies to your situation, you can find a thorough answer to whether you can get Mounjaro if your BMI is 27 alongside a detailed breakdown of how the clinical criteria are applied.

Private treatment versus NHS access at this BMI

NHS access to Mounjaro (tirzepatide) follows the criteria set out in NICE technology appraisal TA1026, which is significantly stricter than the licensed criteria. NHS eligibility currently requires a BMI of at least 35 alongside multiple qualifying comorbidities, delivered through a structured specialist pathway. A BMI of 27 sits well outside the current NHS thresholds, regardless of comorbidities.

For most people at BMI 27 who meet the licensed criteria, private treatment through a regulated online pharmacy is therefore the practical route. The distinction matters: private prescribing operates within the same licensed eligibility framework and the same professional standards (a GPhC-registered prescriber still makes the clinical decision) but without the additional service restrictions and waiting times that come with NHS provision.

Cost is a real consideration when NHS access isn't available. How Mounjaro is priced in the UK private market covers what you should expect to pay and what a legitimate price should include. At nume, a single transparent price covers the consultation, prescription, treatment and next-working-day delivery, no subscription, and a prescriber reviews every repeat order. If you also take metformin and want to understand how the two treatments interact, our page on taking metformin with Mounjaro covers the key clinical considerations. If you're ready to see whether you qualify, check your eligibility with our clinical team.